Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stomach bug treatment may boost blood platelets in ITP patients

NCT ID NCT07150286

Disease control Sponsor: Al-Mustansiriyah University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether treating Helicobacter pylori (a common stomach infection) with antibiotics can raise platelet counts in people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. Researchers enrolled 100 adults with ITP in Baghdad, tested them for H. pylori, and gave those who were positive a 14-day course of antibiotics. Platelet counts were measured before and four weeks after treatment to see if eradicating the infection helped.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Levofloxacin-based triple therapy (antibiotics and acid reducer)
What this could lead to
If successful, this could offer a simple antibiotic treatment to improve platelet counts in some ITP patients, reducing bleeding risk.
What could go wrong
This is a small, completed study in one city, so results may not apply broadly. Not all ITP patients have H. pylori, and antibiotics can cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Sep 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years) with a confirmed diagnosis of ITP Platelet count \<100,000/µL. H. pylori-positive or H. pylori-negative based on stool antigen test Exclusion Criteria: * • Patients with other causes of thrombocytopenia (e.g., leukemia, aplastic anemia). * Severe comorbidities (e.g., uncontrolled diabetes, severe cardiac disease). * Recent use (within 4 weeks) of antibiotics, proton pump inhibitors, or bismuth compounds. * Concurrent use of medications that interfere with H. pylori therapy or platelet levels. * Pregnant or lactating women. * Known allergy or intolerance to eradication therapy agents (clarithromycin, amoxicillin, metronidazole). * High risk of poor compliance (e.g., psychiatric illness).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Helicobacter pylori infectious disease Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helicobacter pylori infections Immune thrombocytopenic purpura

Contacts and locations

Locations

  • Al-Mustansiriyah University - college of pharmacy - clinical pharmacy department

    Baghdad, Baghdad Governorate, 10001, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.